Literature DB >> 70730

[Active enhancement of canine liver allograft by pretreatment with polyspecific spleen alloantigen (author's transl)].

T S Lie, A Holst, M Kanda, P Oehr, G S Rau, H J Biersack, K Rommelsheim, U Grünn.   

Abstract

Because it is not possible to use donor specific antigens for the induction of immunological enhancement in cadaveric organtransplantation, attempts were made to use polyspecific antigens in the enhancement of orthotopic canine liver allotransplants. Of 34 mongrel recipients, 17 controls survived for 6.9 +/- 1.5 days. Six recipients (group 3) were given 750 mg/kg polyspecific, semisoluble antigen prepared from 20 spleens (PSEA 20) together with 10 mg/kg prednisolone on days 15, 8 and 1 before transplantation. The mean survival time of this group was 10.1 +/- 2.0 days (P less than 0.01 compared with the control group). Six other recipients (group 4) were treated similiarly, except that the antigen had been prepared from a pool of 70 spleens (PSEA 70). Survival was variable here: 3 survived for more than 3 weeks and the other 3 died on days 1, 7 and 8 post-operatively, with signs of accelerated rejection. Donors and recipients were not identical for LD determinants, but one donor recipient pair with near identity showed a higher degree of enhancement. The recipients displaying accelerated rejection had markedly higher lymphocytotoxic and haemagglutinating antibodies. Animals surviving for longer periods had low antibody titres. In addition, all recipients progressive rejection were found to show inhibition of leucocyte migration. After three antigen doses rosette-forming lymphocytes were present in increased numbers in peripheral blood, and remained unchanged thereafter.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 70730     DOI: 10.1007/BF01259349

Source DB:  PubMed          Journal:  Langenbecks Arch Chir        ISSN: 0023-8236


  19 in total

1.  Reconstructive problems in canine liver homotransplantation with special reference to the postoperative role of hepatic venous flow.

Authors:  T E STARLZ; H A KAUPP; D R BROCK; R E LAZARUS; R V JOHNSON
Journal:  Surg Gynecol Obstet       Date:  1960-12

2.  Inhibition of spontaneous allorosette formation in rats by serum from tolerant animals.

Authors:  J C Gluckman; R E Hargreaves; K E Hellström
Journal:  Transplantation       Date:  1974-05       Impact factor: 4.939

3.  Thymus dependency of rosette-forming cells: evidence for a circulating thymic hormone.

Authors:  J F Bach; M Dardenne
Journal:  Transplant Proc       Date:  1972-09       Impact factor: 1.066

4.  Renal transplantation in the inbred rat. XIX. In vitro correlates of enhancement induction.

Authors:  R D Guttmann
Journal:  Transplantation       Date:  1973-06       Impact factor: 4.939

5.  Prolongation of skin allograft survival with spleen extracts and antilymphocytic serum.

Authors:  L Brent; P J Kilshaw
Journal:  Nature       Date:  1970-08-29       Impact factor: 49.962

6.  Serotyping for homotransplantation. 18. Refinement of microdroplet lymphocyte cytotoxicity test.

Authors:  K K Mittal; M R Mickey; D P Singal; P I Terasaki
Journal:  Transplantation       Date:  1968-11       Impact factor: 4.939

7.  Detection of serum-blocking factors by inhibition of allorosette formation in rats with long-surviving renal allografts following short-term postoperative ALS treatment.

Authors:  T S Lie; M Kanda; W I Kim; P Oehr; A Holst; S K Choi; H J Biersack
Journal:  Transplantation       Date:  1977-01       Impact factor: 4.939

8.  Active enhancement of rat kidney allografts. Effect of pretreatment with prednisolone and donor-specific antigen.

Authors:  T S Lie; H Ebata; W I Kim; U Grünn
Journal:  Transplantation       Date:  1976-02       Impact factor: 4.939

9.  Changes in leucocyte migration after renal transplantation.

Authors:  M G Smith; A L Eddleston; J A Dominguez; D B Evans; M Bewick; R Williams
Journal:  Br Med J       Date:  1969-11-01

10.  Active enhancement of canine liver allografts--effect of pretreatment with prednisolone and donor-specific antigen.

Authors:  T S Lie; H Nakano; W Bumanowski; K Rommelsheim
Journal:  Surgery       Date:  1976-11       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.